# EDGAR Filing Document

**Accession Number:** 0001711754
**File Stem:** 0001213900-25-078041
**Filing Date:** 2025-8
**Character Count:** 5060
**Document Hash:** d096a3f36e88fee1f933d51f7c0029d6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-078041.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001213900-25-078041

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250804

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ellspermann Cory Randall
- **CENTRAL INDEX KEY:** 0002082083

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38793
- **FILM NUMBER:** 251229197

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD., SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inmune Bio, Inc.
- **CENTRAL INDEX KEY:** 0001711754
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475205835
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 8589643720

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ellspermann Cory Randall<br><sub>(Last) (First) (Middle)</sub><br>C/O INMUNE BIO INC.<br>225 NE MIZNER BLVD., SUITE 640<br><sub>(Street)</sub><br>BOCA RATON, FL 33432<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Inmune Bio, Inc. [ INMB ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-08-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Interim CFO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options | <sup>(1)</sup> | 2029-11-24 | Common Stock | 75000 | $3.91 | D |  |
| Stock Options | <sup>(1)</sup> | 2031-07-22 | Common Stock | 40000 | $21.06 | D |  |
| Stock Options | <sup>(1)</sup> | 2032-03-20 | Common Stock | 30000 | $7.92 | D |  |
| Stock Options | <sup>(2)</sup> | 2034-05-13 | Common Stock | 30000 | $9.92 | D |  |
| Stock Options | <sup>(3)</sup> | 2034-12-04 | Common Stock | 70000 | $5.05 | D |  |

---

### Footnotes:

(1) The option is fully vested.

(2) The option vested or vests as to one-forty-eighth (1/48) of the total award monthly, with the first tranche vesting on June 14, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the Reporting Person's continued service with the Issuer on each vesting date.

(3) The option vests and becomes exercisable on December 5, 2026, subject to the Reporting Person's continued service with the Issuer on the vesting date.

**Signature:** /s/ CORY RANDALL ELLSPERMANN  
**Date:** 2025-08-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**